Health Economics›Soft tissue sarcoma›Locally advanced or metastatic disease first-line therapy

Locally advanced or metastatic disease first-line therapy

Soft tissue sarcoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Docetaxel and Gemcitabine Variant #01	—	R 6 266	21d	~6.2 mo	—	~9	~R 56 391 PFS proxy · indirect	1
Doxorubicin monotherapy Variant #01	—	R 902	21d	5.4 mo	19.0 mo	9	R 8 114 PFS proxy	6
Doxorubicin and Olaratumab Variant #01 Partial	—	R 789	21d	—	20.4 mo	9	R 6 311 PFS proxy	1

3 of 3 regimens shown